193 related articles for article (PubMed ID: 2965123)
1. Teicoplanin in the treatment of skin and soft tissue infections.
Turpin PJ; Taylor GP; Logan MN; Wood MJ
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():117-22. PubMed ID: 2965123
[TBL] [Abstract][Full Text] [Related]
2. Intravenous or intramuscular teicoplanin once daily for skin and soft-tissue infections.
Edelstein HE; Oster SE; Chirurgi VA; Karp RA; Cassano KB; McCabe RE
DICP; 1991 Sep; 25(9):914-8. PubMed ID: 1835223
[TBL] [Abstract][Full Text] [Related]
3. Teicoplanin, a new antibiotic effective against gram-positive bacterial infections of the skin and soft tissues.
Bochud-Gabellon I; Regamey C
Dermatologica; 1988; 176(1):29-38. PubMed ID: 2962889
[TBL] [Abstract][Full Text] [Related]
4. Treatment of bone and soft tissue infections with teicoplanin.
Marone P; Concia E; Andreoni M; Suter F; Cruciani M
J Antimicrob Chemother; 1990 Mar; 25(3):435-9. PubMed ID: 2140111
[TBL] [Abstract][Full Text] [Related]
5. Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients.
Lemerle S; de La Rocque F; Lamy R; Fremaux A; Bernaudin F; Lobut JB; Reinert P
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():113-6. PubMed ID: 2965122
[TBL] [Abstract][Full Text] [Related]
6. Teicoplanin in the treatment of skin and soft tissue infections: results of a multicentre study.
Lang E; Földes M; Marghescu S
Infection; 1991; 19(3):190-4. PubMed ID: 1832418
[TBL] [Abstract][Full Text] [Related]
7. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.
de Lalla F; Santoro D; Rinaldi E; Suter F; Cruciani M; Guaglianone MH; Rizzardini G; Pellegata G
J Antimicrob Chemother; 1989 Jan; 23(1):131-42. PubMed ID: 2526109
[TBL] [Abstract][Full Text] [Related]
8. Open study of teicoplanin in gram-positive infections.
Walsh B; Drabu YJ; Mehtar S; Blakemore PH
Int J Clin Pharmacol Res; 1988; 8(2):99-100. PubMed ID: 2967801
[TBL] [Abstract][Full Text] [Related]
9. Treatment of infections by staphylococci and other gram-positive bacteria with teicoplanin: an open study.
Pauluzzi S; Del Favero A; Menichetti F; Baratta E; Moretti VM; Di Filippo P; Pasticci MB; Guerciolini R; Patoia L; Frongillo RF
J Antimicrob Chemother; 1987 Sep; 20(3):431-8. PubMed ID: 2960643
[TBL] [Abstract][Full Text] [Related]
10. Activity of teicoplanin in localized experimental infections in rats.
Arioli V; Berti M; Candiani G
J Hosp Infect; 1986 Mar; 7 Suppl A():91-9. PubMed ID: 2871103
[TBL] [Abstract][Full Text] [Related]
11. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci.
Harding I; Garaud JJ
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():93-103. PubMed ID: 2965137
[TBL] [Abstract][Full Text] [Related]
12. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria.
Lewis P; Garaud JJ; Parenti F
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():61-7. PubMed ID: 2965133
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.
Glupczynski Y; Lagast H; Van der Auwera P; Thys JP; Crokaert F; Yourassowsky E; Meunier-Carpentier F; Klastersky J; Kains JP; Serruys-Schoutens E
Antimicrob Agents Chemother; 1986 Jan; 29(1):52-7. PubMed ID: 2942100
[TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin for soft tissue infections.
Wood MJ; Logan MN
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():159-64. PubMed ID: 3804904
[TBL] [Abstract][Full Text] [Related]
15. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
LeFrock JL; Ristuccia AM; Ristuccia PA; Quenzer RW; Haggerty PG; Allen JE; Lettau LA; Schwartz R; Appleby D
Eur J Surg Suppl; 1992; (567):9-13. PubMed ID: 1381644
[TBL] [Abstract][Full Text] [Related]
16. [Teicoplanin and Gram-positive coccus infections. Results of a multicenter study on 66 cases].
Dureux JB; Canton P; Chavanet P; Chippaux C; Dupeyron JP; Estavoyer JM; Giorgi C; Jaeger A; Jehl F; Kazmierzack A
Pathol Biol (Paris); 1987 May; 35(5):511-5. PubMed ID: 2956564
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.
Bibler MR; Frame PT; Hagler DN; Bode RB; Staneck JL; Thamlikitkul V; Harris JE; Haregewoin A; Bullock WE
Antimicrob Agents Chemother; 1987 Feb; 31(2):207-12. PubMed ID: 2952062
[TBL] [Abstract][Full Text] [Related]
18. Spanish experience with teicoplanin.
Fernández-Guerrero M; Gobernado M; Ariza J; Williams A
Scand J Infect Dis Suppl; 1990; 72():38-44. PubMed ID: 2151066
[TBL] [Abstract][Full Text] [Related]
19. Therapy of serious gram-positive infections with teicoplanin.
Davies AJ; Stone JM; Synott M
Drugs Exp Clin Res; 1989; 15(1):29-31. PubMed ID: 2526010
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections.
Kempf P; Pompetzki H; Oppermann A; Wittenberger R; Siebert J; Fell JJ; Dieterich HA
Infection; 1989; 17(3):177-81. PubMed ID: 2525529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
